Shorla Oncology Company Profile
✉ Email this page to a colleague
What is the competitive landscape for SHORLA ONCOLOGY
SHORLA ONCOLOGY has one approved drug.
There is one US patent protecting SHORLA ONCOLOGY drugs.
There are six patent family members on SHORLA ONCOLOGY drugs in six countries and five supplementary protection certificates in five countries.
Summary for Shorla Oncology
| International Patents: | 6 |
| US Patents: | 1 |
| Tradenames: | 1 |
| Ingredients: | 1 |
| NDAs: | 1 |
Drugs and US Patents for Shorla Oncology
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shorla Oncology | IMKELDI | imatinib mesylate | SOLUTION;ORAL | 219097-001 | Nov 22, 2024 | RX | Yes | Yes | 11,957,681 | ⤷ Start Trial | Y | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
International Patents for Shorla Oncology Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Russian Federation | 2020108342 | ⤷ Start Trial |
| Australia | 2018306149 | ⤷ Start Trial |
| European Patent Office | 3658190 | ⤷ Start Trial |
| China | 111278466 | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for Shorla Oncology Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 0564409 | C00564409/01 | Switzerland | ⤷ Start Trial | PRODUCT NAME: IMATINIB; REGISTRATION NO/DATE: IKS 55807 20010621 |
| 0564409 | 02C0012 | France | ⤷ Start Trial | PRODUCT NAME: IMATINIB MESILATE; NAT. REGISTRATION NO/DATE: EU/1/01/198/001 20011107; FIRST REGISTRATION: LI - IKS 55 807 20010621 |
| 0564409 | C300086 | Netherlands | ⤷ Start Trial | PRODUCT NAME: IMATINIB, DESGEWENST IN DE VORM VAN EEN FARMACEUTISCH AANVAARDBAAR ZUURADDITIEZOUT, IN HET BIJZONDER HET MESILAAT; NATL. REGISTRATION NO/DATE: EU/1/01/198/001 - 006 20011107; FIRST REGISTRATION: CH IKS 55807 20010621 |
| 0564409 | 2002/005 | Ireland | ⤷ Start Trial | PRODUCT NAME: IMATINIB OR ONE OF ITS PHARMACEUTICALLY ACCEPTABLE ACID ADDITION SALTS, ESPECIALLY THE MONOMETHANESULFONATE SALT; NAT REGISTRATION NO/DATE: EU/1/01/198/001-006 20011107; FIRST REGISTRATION NO/DATE: CH 55807 55807 01 55807 02 20010621; PAEDIATRIC INVESTIGATION PLAN: P/0028/2012 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
